# Array Technologies, Inc.: financial statements, quarterly

ARRY · Nasdaq · CIK 1820721 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/arry.md) · [Financials](/companies/arry/financials.md) · [Filings](/companies/arry/filings.md) · [Insiders](/companies/arry/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/arry/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [350](/filings/0001820721-24-000076.md) | [342 d](/filings/0001820721-26-000008.md) | [153](/filings/0001820721-25-000060.md) | [256](/filings/0001820721-25-000085.md) | [231](/filings/0001820721-25-000095.md) | [275 d](/filings/0001820721-26-000008.md) | [302](/filings/0001628280-26-031453.md) | [362](/filings/0001628280-26-053517.md) | [393](/filings/0001820721-25-000095.md) | [226 d](/filings/0001820721-26-000008.md) | [223](/filings/0001628280-26-031453.md) | [342](/filings/0001628280-26-053517.md) |
| Cost of revenue | $m | [263](/filings/0001820721-24-000076.md) | [257 d](/filings/0001820721-26-000008.md) | [98.3](/filings/0001820721-25-000060.md) | [170](/filings/0001820721-25-000085.md) | [153](/filings/0001820721-25-000095.md) | [197 d](/filings/0001820721-26-000008.md) | [226](/filings/0001628280-26-031453.md) | [265](/filings/0001628280-26-053517.md) | [288](/filings/0001820721-25-000095.md) | [207 d](/filings/0001820721-26-000008.md) | [160](/filings/0001628280-26-031453.md) | [242](/filings/0001628280-26-053517.md) |
| Gross profit | $m | [87.4](/filings/0001820721-24-000076.md) | [84.2 d](/filings/0001820721-26-000008.md) | [55.1](/filings/0001820721-25-000060.md) | [86.0](/filings/0001820721-25-000085.md) | [78.3](/filings/0001820721-25-000095.md) | [78.3 d](/filings/0001820721-26-000008.md) | [76.4](/filings/0001628280-26-031453.md) | [97.1](/filings/0001628280-26-053517.md) | [106](/filings/0001820721-25-000095.md) | [19.3 d](/filings/0001820721-26-000008.md) | [63.0](/filings/0001628280-26-031453.md) | [99.6](/filings/0001628280-26-053517.md) |
| Research and development | $m | [2.0](/filings/0001820721-24-000076.md) | [2.1 d](/filings/0001820721-26-000008.md) | [1.9](/filings/0001820721-25-000060.md) | [1.8](/filings/0001820721-25-000085.md) | [1.6](/filings/0001820721-25-000095.md) | [1.4 d](/filings/0001820721-26-000008.md) | [2.4](/filings/0001628280-26-031453.md) | [2.5](/filings/0001628280-26-053517.md) | [2.3](/filings/0001820721-25-000095.md) | [2.7 d](/filings/0001820721-26-000008.md) | [3.0](/filings/0001628280-26-031453.md) | [5.0](/filings/0001628280-26-053517.md) |
| Operating income | $m | [40.2](/filings/0001820721-24-000076.md) | [30.2 d](/filings/0001820721-26-000008.md) | [8.4](/filings/0001820721-25-000060.md) | [39.6](/filings/0001820721-25-000085.md) | [(133)](/filings/0001820721-25-000095.md) | [(142) d](/filings/0001820721-26-000008.md) | [27.3](/filings/0001628280-26-031453.md) | [46.4](/filings/0001628280-26-053517.md) | [45.5](/filings/0001820721-25-000095.md) | [(148) d](/filings/0001820721-26-000008.md) | [7.1](/filings/0001628280-26-031453.md) | [34.8](/filings/0001628280-26-053517.md) |
| Interest expense | $m | [13.1](/filings/0001820721-23-000171.md) | [8.9 d](/filings/0001820721-24-000011.md) | [8.9](/filings/0001820721-24-000049.md) | [8.6](/filings/0001820721-25-000085.md) | [8.3](/filings/0001820721-25-000095.md) | [9.0 d](/filings/0001820721-26-000008.md) | [8.0](/filings/0001628280-26-031453.md) | [8.8](/filings/0001628280-26-053517.md) | [5.0](/filings/0001820721-25-000095.md) | [5.5 d](/filings/0001820721-26-000008.md) | [5.6](/filings/0001628280-26-031453.md) | [5.8](/filings/0001628280-26-053517.md) |
| Income tax | $m | [7.2](/filings/0001820721-24-000076.md) | [3.0 d](/filings/0001820721-26-000008.md) | [1.3](/filings/0001820721-25-000060.md) | [7.8](/filings/0001820721-25-000085.md) | [3.9](/filings/0001820721-25-000095.md) | [(23.1) d](/filings/0001820721-26-000008.md) | [6.5](/filings/0001628280-26-031453.md) | [13.6](/filings/0001628280-26-053517.md) | [9.9](/filings/0001820721-25-000095.md) | [(7.1) d](/filings/0001820721-26-000008.md) | [2.1](/filings/0001628280-26-031453.md) | [7.4](/filings/0001628280-26-053517.md) |
| Net income | $m | [23.1](/filings/0001820721-24-000076.md) | [19.3 d](/filings/0001820721-26-000008.md) | [2.2](/filings/0001820721-25-000060.md) | [25.7](/filings/0001820721-25-000085.md) | [(141)](/filings/0001820721-25-000095.md) | [(127) d](/filings/0001820721-26-000008.md) | [16.7](/filings/0001628280-26-031453.md) | [43.3](/filings/0001628280-26-053517.md) | [33.5](/filings/0001820721-25-000095.md) | [(146) d](/filings/0001820721-26-000008.md) | [2.0](/filings/0001628280-26-031453.md) | [24.3](/filings/0001628280-26-053517.md) |
| Diluted EPS | $ per share | [0.07](/filings/0001820721-24-000076.md) | not reported | [(0.07)](/filings/0001820721-25-000060.md) | [0.08](/filings/0001820721-25-000085.md) | [(1.02)](/filings/0001820721-25-000095.md) | not reported | [0.02](/filings/0001628280-26-031453.md) | [0.19](/filings/0001628280-26-053517.md) | [0.12](/filings/0001820721-25-000095.md) | not reported | [(0.09)](/filings/0001628280-26-031453.md) | [0.05](/filings/0001628280-26-053517.md) |
| Basic EPS | $ per share | [0.07](/filings/0001820721-24-000076.md) | not reported | [(0.07)](/filings/0001820721-25-000060.md) | [0.08](/filings/0001820721-25-000085.md) | [(1.02)](/filings/0001820721-25-000095.md) | not reported | [0.02](/filings/0001628280-26-031453.md) | [0.19](/filings/0001628280-26-053517.md) | [0.12](/filings/0001820721-25-000095.md) | not reported | [(0.09)](/filings/0001628280-26-031453.md) | [0.05](/filings/0001628280-26-053517.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [174](/filings/0001820721-23-000171.md) | [249](/filings/0001820721-25-000023.md) | [288](/filings/0001820721-24-000049.md) | [282](/filings/0001820721-24-000062.md) | [332](/filings/0001820721-24-000076.md) | [363](/filings/0001820721-26-000008.md) | [348](/filings/0001820721-25-000060.md) | [377](/filings/0001820721-25-000085.md) | [222](/filings/0001820721-25-000095.md) | [244](/filings/0001628280-26-053517.md) | [201](/filings/0001628280-26-031453.md) | [307](/filings/0001628280-26-053517.md) |
| Current assets | $m | [863](/filings/0001820721-23-000171.md) | [832](/filings/0001820721-25-000023.md) | [774](/filings/0001820721-24-000049.md) | [849](/filings/0001820721-24-000062.md) | [902](/filings/0001820721-24-000076.md) | [999](/filings/0001820721-26-000008.md) | [976](/filings/0001820721-25-000060.md) | [1,038](/filings/0001820721-25-000085.md) | [867](/filings/0001820721-25-000095.md) | [869](/filings/0001628280-26-053517.md) | [879](/filings/0001628280-26-031453.md) | [892](/filings/0001628280-26-053517.md) |
| Total assets | $m | [1,779](/filings/0001820721-23-000171.md) | [1,707](/filings/0001820721-25-000023.md) | [1,629](/filings/0001820721-24-000049.md) | [1,652](/filings/0001820721-24-000062.md) | [1,563](/filings/0001820721-24-000076.md) | [1,426](/filings/0001820721-26-000008.md) | [1,426](/filings/0001820721-25-000060.md) | [1,542](/filings/0001820721-25-000085.md) | [1,611](/filings/0001820721-25-000095.md) | [1,452](/filings/0001628280-26-053517.md) | [1,475](/filings/0001628280-26-031453.md) | [1,534](/filings/0001628280-26-053517.md) |
| Current liabilities | $m | [401](/filings/0001820721-23-000171.md) | [336](/filings/0001820721-25-000023.md) | [284](/filings/0001820721-24-000049.md) | [338](/filings/0001820721-24-000062.md) | [375](/filings/0001820721-24-000076.md) | [438](/filings/0001820721-26-000008.md) | [408](/filings/0001820721-25-000060.md) | [468](/filings/0001820721-25-000085.md) | [458](/filings/0001820721-25-000095.md) | [377](/filings/0001628280-26-053517.md) | [390](/filings/0001628280-26-031453.md) | [406](/filings/0001628280-26-053517.md) |
| Total liabilities | $m | [1,162](/filings/0001820721-23-000171.md) | [1,096](/filings/0001820721-25-000023.md) | [1,033](/filings/0001820721-24-000049.md) | [1,073](/filings/0001820721-24-000062.md) | [1,106](/filings/0001820721-24-000076.md) | [1,137](/filings/0001820721-26-000008.md) | [1,102](/filings/0001820721-25-000060.md) | [1,177](/filings/0001820721-25-000085.md) | [1,207](/filings/0001820721-25-000095.md) | [1,191](/filings/0001628280-26-053517.md) | [1,207](/filings/0001628280-26-031453.md) | [1,238](/filings/0001628280-26-053517.md) |
| Long-term debt | $m | [659](/filings/0001820721-23-000171.md) | [661](/filings/0001820721-25-000023.md) | [658](/filings/0001820721-24-000049.md) | [652](/filings/0001820721-24-000062.md) | [648](/filings/0001820721-24-000076.md) | [647](/filings/0001820721-26-000008.md) | [645](/filings/0001820721-25-000060.md) | [658](/filings/0001820721-25-000085.md) | [658](/filings/0001820721-25-000095.md) | [659](/filings/0001628280-26-053517.md) | [657](/filings/0001628280-26-031453.md) | [658](/filings/0001628280-26-053517.md) |
| Current portion of debt | $m | [38.8](/filings/0001820721-23-000171.md) | [21.5](/filings/0001820721-25-000023.md) | [22.5](/filings/0001820721-24-000049.md) | [29.2](/filings/0001820721-24-000062.md) | [28.1](/filings/0001820721-24-000076.md) | [30.7](/filings/0001820721-26-000008.md) | [34.5](/filings/0001820721-25-000060.md) | [36.3](/filings/0001820721-25-000085.md) | [22.6](/filings/0001820721-25-000095.md) | [10.3](/filings/0001628280-26-053517.md) | [9.5](/filings/0001628280-26-031453.md) | [0.0](/filings/0001628280-26-053517.md) |
| Shareholders' equity | $m | [229](/filings/0001820721-24-000076.md) | [259](/filings/0001820721-26-000008.md) | [231](/filings/0001820721-25-000085.md) | [200](/filings/0001820721-25-000095.md) | [64.5](/filings/0001820721-25-000095.md) | [(118)](/filings/0001628280-26-053517.md) | [(97.8)](/filings/0001628280-26-053517.md) | [(70.9)](/filings/0001628280-26-053517.md) | [(46.7)](/filings/0001820721-25-000095.md) | [(206)](/filings/0001628280-26-053517.md) | [(214)](/filings/0001628280-26-053517.md) | [(202)](/filings/0001628280-26-053517.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [71.6 d](/filings/0001820721-24-000076.md) | [94.0 d](/filings/0001820721-26-000008.md) | [47.5](/filings/0001820721-25-000060.md) | [4.0 d](/filings/0001820721-25-000085.md) | [44.9 d](/filings/0001820721-25-000095.md) | [57.6 d](/filings/0001820721-26-000008.md) | [(13.1)](/filings/0001628280-26-031453.md) | [43.8 d](/filings/0001628280-26-053517.md) | [27.4 d](/filings/0001820721-25-000095.md) | [43.6 d](/filings/0001820721-26-000008.md) | [(29.4)](/filings/0001628280-26-031453.md) | [121 d](/filings/0001628280-26-053517.md) |
| Capital expenditure | $m | [2.2 d](/filings/0001820721-24-000076.md) | [5.4 d](/filings/0001820721-26-000008.md) | [2.4](/filings/0001820721-25-000060.md) | [2.1 d](/filings/0001820721-25-000085.md) | [1.1 d](/filings/0001820721-25-000095.md) | [1.7 d](/filings/0001820721-26-000008.md) | [2.4](/filings/0001628280-26-031453.md) | [6.6 d](/filings/0001628280-26-053517.md) | [5.5 d](/filings/0001820721-25-000095.md) | [7.5 d](/filings/0001820721-26-000008.md) | [7.5](/filings/0001628280-26-031453.md) | [7.6 d](/filings/0001628280-26-053517.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [151](/filings/0001820721-23-000171.md) | [152](/filings/0001820721-24-000049.md) | [152](/filings/0001820721-24-000062.md) | [152](/filings/0001820721-24-000076.md) | [151](/filings/0001820721-25-000060.md) | [152](/filings/0001820721-25-000085.md) | [152](/filings/0001820721-25-000095.md) | [153](/filings/0001628280-26-031453.md) | [153](/filings/0001628280-26-053517.md) | [154](/filings/0001820721-25-000095.md) | [153](/filings/0001628280-26-031453.md) | [156](/filings/0001628280-26-053517.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 154,007,692 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001628280-26-053517.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.